FDA expands accelerated approval of oral sevabertinib for first-line HER2-mutant lung cancer, offering targeted treatment with strong response rates versus standard chemotherapy.
PBM, employer and pharmacy leaders at the Pharmacy Benefit Management Institute annual meeting said actionable data and real-time technology, not just transparency, are needed to control rising costs.
Patients with challenging cases of atrial fibrillation (AFib) have a new treatment option now that the FDA has approved ...
A new review says outcome tools like IHS4-55 and HiSQOL should replace or supplement HiSCR to better measure hidradenitis suppurativa treatment success.
Kaiser Permanente’s contracting emphasizes acquisition cost and total value, enabling savings to flow to the health system ...
Researchers found that women with endometriosis had an overall 46% higher risk of developing Type 2 diabetes, with risk varying across different forms of endometriosis. The risk was highest among ...
Vertex’s Journavx (suzetrigine) allowed 76.1% of patients to recover from laparoscopic or arthroscopic surgery without a ...
Biosimilars are on just about everyone's radar, and if recent market projections come to fruition, that is going to be truer ...
In this discussion, Julia S. Feldman, Ph.D., a postdoctoral fellow in the Department of Psychiatry at the University of ...
University of Maryland researchers used machine learning models trained on claims data of adults with diabetes to predict ...
Across the country, nearly three in four adults are living with at least one chronic condition. Yet for many people, managing ...
Rapid growth in rare disease innovation increases demand for specialty pharmacists skilled in REMS, monitoring, education, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results